Ad is loading...
ABUS
Price
$3.68
Change
+$0.05 (+1.38%)
Updated
Dec 6, 04:59 PM (EDT)
82 days until earnings call
ALDX
Price
$5.21
Change
+$0.27 (+5.45%)
Updated
Dec 6, 04:59 PM (EDT)
89 days until earnings call
Ad is loading...

ABUS vs ALDX

Header iconABUS vs ALDX Comparison
Open Charts ABUS vs ALDXBanner chart's image
Arbutus Biopharma
Price$3.68
Change+$0.05 (+1.38%)
Volume$4.41K
CapitalizationN/A
Aldeyra Therapeutics
Price$5.21
Change+$0.27 (+5.45%)
Volume$2.15K
CapitalizationN/A
ABUS vs ALDX Comparison Chart
Loading...
ABUS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
ALDX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
ABUS vs. ALDX commentary
Dec 08, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABUS is a Sell and ALDX is a Buy.

COMPARISON
Comparison
Dec 08, 2024
Stock price -- (ABUS: $3.68 vs. ALDX: $5.22)
Brand notoriety: ABUS and ALDX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABUS: 56% vs. ALDX: 86%
Market capitalization -- ABUS: $687.85M vs. ALDX: $294.77M
ABUS [@Biotechnology] is valued at $687.85M. ALDX’s [@Biotechnology] market capitalization is $294.77M. The market cap for tickers in the [@Biotechnology] industry ranges from $489.7B to $0. The average market capitalization across the [@Biotechnology] industry is $2.71B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABUS’s FA Score shows that 0 FA rating(s) are green whileALDX’s FA Score has 0 green FA rating(s).

  • ABUS’s FA Score: 0 green, 5 red.
  • ALDX’s FA Score: 0 green, 5 red.
According to our system of comparison, ALDX is a better buy in the long-term than ABUS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABUS’s TA Score shows that 4 TA indicator(s) are bullish while ALDX’s TA Score has 5 bullish TA indicator(s).

  • ABUS’s TA Score: 4 bullish, 6 bearish.
  • ALDX’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, ALDX is a better buy in the short-term than ABUS.

Price Growth

ABUS (@Biotechnology) experienced а +6.36% price change this week, while ALDX (@Biotechnology) price change was +6.53% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.01%. For the same industry, the average monthly price growth was -2.68%, and the average quarterly price growth was +10.76%.

Reported Earning Dates

ABUS is expected to report earnings on Feb 27, 2025.

ALDX is expected to report earnings on Mar 06, 2025.

Industries' Descriptions

@Biotechnology (-1.01% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABUS($688M) has a higher market cap than ALDX($295M). ALDX (48.718) and ABUS (47.200) have similar YTD gains . ALDX has higher annual earnings (EBITDA): -42.57M vs. ABUS (-75.14M). ABUS has more cash in the bank: 128M vs. ALDX (113M). ABUS has less debt than ALDX: ABUS (1.45M) vs ALDX (15.6M). ABUS has higher revenues than ALDX: ABUS (6.74M) vs ALDX (0).
ABUSALDXABUS / ALDX
Capitalization688M295M233%
EBITDA-75.14M-42.57M176%
Gain YTD47.20048.71897%
P/E RatioN/AN/A-
Revenue6.74M0-
Total Cash128M113M113%
Total Debt1.45M15.6M9%
FUNDAMENTALS RATINGS
ABUS vs ALDX: Fundamental Ratings
ABUS
ALDX
OUTLOOK RATING
1..100
515
VALUATION
overvalued / fair valued / undervalued
1..100
65
Fair valued
41
Fair valued
PROFIT vs RISK RATING
1..100
58100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
5251
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ALDX's Valuation (41) in the Biotechnology industry is in the same range as ABUS (65). This means that ALDX’s stock grew similarly to ABUS’s over the last 12 months.

ABUS's Profit vs Risk Rating (58) in the Biotechnology industry is somewhat better than the same rating for ALDX (100). This means that ABUS’s stock grew somewhat faster than ALDX’s over the last 12 months.

ABUS's SMR Rating (100) in the Biotechnology industry is in the same range as ALDX (100). This means that ABUS’s stock grew similarly to ALDX’s over the last 12 months.

ALDX's Price Growth Rating (51) in the Biotechnology industry is in the same range as ABUS (52). This means that ALDX’s stock grew similarly to ABUS’s over the last 12 months.

ALDX's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ABUS (100). This means that ALDX’s stock grew similarly to ABUS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABUSALDX
RSI
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
80%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
82%
MACD
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 16 days ago
80%
Bullish Trend 13 days ago
82%
Declines
ODDS (%)
Bearish Trend 12 days ago
78%
Bearish Trend 5 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
88%
View a ticker or compare two or three
Ad is loading...
ABUS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
ALDX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HSCYX31.490.24
+0.77%
Hartford Small Company Y
OTCFX69.040.12
+0.17%
T. Rowe Price Small-Cap Stock
FIKWX12.250.02
+0.16%
Fidelity Advisor Asset Manager 30% Z
YASLX11.23N/A
N/A
AMG Yacktman Special Opportunities Z
BHCHX20.44-0.03
-0.15%
Baron Health Care Instl

ABUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABUS has been loosely correlated with ARRY. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ABUS jumps, then ARRY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABUS
1D Price
Change %
ABUS100%
+1.38%
ARRY - ABUS
43%
Loosely correlated
-5.86%
AXON - ABUS
42%
Loosely correlated
-0.30%
ROIV - ABUS
38%
Loosely correlated
+2.32%
VCYT - ABUS
38%
Loosely correlated
+3.01%
VIR - ABUS
38%
Loosely correlated
+4.77%
More

ALDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALDX has been loosely correlated with CANF. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ALDX jumps, then CANF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALDX
1D Price
Change %
ALDX100%
+5.45%
CANF - ALDX
46%
Loosely correlated
+5.23%
FOLD - ALDX
44%
Loosely correlated
-0.31%
ABSI - ALDX
41%
Loosely correlated
+6.51%
CRSP - ALDX
41%
Loosely correlated
+5.70%
NTLA - ALDX
41%
Loosely correlated
+7.84%
More